Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants.
LY255582, administered subcutaneously, decreased food intake and body weight gain of fed obese Zucker rats during the entire 30-day period of treatment. No tolerance to these biologic effects of LY255582 could be demonstrated. d-Amphetamine and naltrexone, administered subcutaneously, and d,l-fenfluramine and salbutamol, administered orally, decreased food intake for no more than 6 to 12 days, in contrast to the long-lasting effects of LY255582. Salbutamol suppressed the appetite of obese rats for 3-4 days only. After an additional 12 days of treatment, weight gain decreased significantly accompanied by no appetite suppression. Thus, there is a difference in the duration of action of the opioid antagonist, LY255582, when compared to amphetamine, fenfluramine, naltrexone, and salbutamol, on food intake and body weight gain of obese rats.
Shaw
W N
WN
Diabetes Research, Lilly Research Laboratories, Indianapolis, IN 46825.
D000420:Albuterol / Q000494:pharmacology; D000818:Animals; D001067:Appetite Depressants / Q000494:pharmacology*; D003510:Cyclohexanes / Q000494:pharmacology*; D003913:Dextroamphetamine / Q000494:pharmacology; D004361:Drug Tolerance; D004435:Eating / Q000187:drug effects*; D004723:Endorphins / Q000037:antagonists & inhibitors*; D005260:Female; D005277:Fenfluramine / Q000494:pharmacology; D007279:Injections, Subcutaneous; D008297:Male; D009271:Naltrexone / Q000494:pharmacology; D009765:Obesity / Q000523:psychology*; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D011924:Rats, Zucker; D015430:Weight Gain / Q000187:drug effects
D001067:Appetite Depressants; D003510:Cyclohexanes; D004723:Endorphins; D010880:Piperidines; C070736:LY 243670; D005277:Fenfluramine; D009271:Naltrexone; D000420:Albuterol; D003913:Dextroamphetamine